Previous 10 | Next 10 |
Registration-enabling Phase 3 segment of RINGSIDE is enrolling patients globally Updated data on AL102 Phase 2 segment of RINGSIDE are planned for presentation at a medical meeting in 2023 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceutic...
Advaxis press release ( OTCQX:ADXS ): FY GAAP EPS of -$8.46. Revenue of $0.25M, compared with $3.2M for the fiscal year 2021. Cash position On October 31, 2022, the consolidated cash and cash equivalents position was $25.2M. For further details see: Advaxis GAAP EPS of -...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company,...
REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytoge...
Ayala Pharmaceuticals' ( NASDAQ: AYLA ) last day of trading is at market close Wednesday as the company's merger with Advaxis ( OTCQX:ADXS ) takes place. Advaxis ( OTCQX:ADXS ) is up 26% . Ayala ( AYLA ) stockholders will own ~62.5% of the combined company, while t...
Ayala Pharmaceuticals ( NASDAQ: AYLA ) and Advaxis ( OTCQX:ADXS ) are merging in an all stock transaction to focus on the development of cancer therapies. Under the agreement, each outstanding common share of Ayala will be converted into the right to receive com...
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders w...
Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders w...
Advaxis press release ( OTCQX:ADXS ): Q3 GAAP EPS of -$3.83. As of July 31, 2022, the company had ~$28.2M in cash and cash equivalents. For further details see: Advaxis GAAP EPS of -$3.83
Announced completion of first dose level and enrollment initiation for second dose level in investigator-sponsored study of ADXS-504 in biochemically recurrent prostate cancer Cash runway extends into fiscal third quarter of 2024 MONMOUTH JUNCTION, N.J., Sept. 12, 2022 (GL...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...